A61K 2039/55561
Cpg containing adjuvants
Official title: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
A61K2039/55561 (Cpg containing adjuvants) appears on 1,147 US grants and 2,366 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,147
- Published applications
- 2,366
- Assignees
- 881
- Inventors
- 3,646
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 1 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 7 | 6 |
| 2002 | 7 | 20 |
| 2003 | 10 | 68 |
| 2004 | 11 | 86 |
| 2005 | 7 | 83 |
| 2006 | 9 | 65 |
| 2007 | 17 | 71 |
| 2008 | 21 | 59 |
| 2009 | 28 | 82 |
| 2010 | 41 | 67 |
| 2011 | 38 | 112 |
| 2012 | 45 | 67 |
| 2013 | 38 | 52 |
| 2014 | 46 | 61 |
| 2015 | 45 | 86 |
| 2016 | 59 | 102 |
| 2017 | 58 | 90 |
| 2018 | 73 | 100 |
| 2019 | 78 | 123 |
| 2020 | 89 | 140 |
| 2021 | 109 | 146 |
| 2022 | 76 | 146 |
| 2023 | 70 | 178 |
| 2024 | 48 | 142 |
| 2025 | 61 | 126 |
| 2026 | 50 | 88 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Preventing and treating amyloid-beta deposition by stimulation of innate immunity6 Oct 2026US 12,751,964 B2New York University
- 3′3′ cyclic dinucleotides containing isonucleotidic units15 Sep 2026US 12,735,445 B2Institute of Organic Chemistry and Biochemistry AS Cr, V. V. I.
- Use of membrane inhibitors to enhance vaccine development against enveloped viruses8 Sep 2026US 12,728,161 B2Cornell University
- Sequential heterologous boost oncolytic viral immunotherapy25 Aug 2026US 12,714,733 B2Children's Hospital of Eastern Ontario Research Institute Inc.
- Methods and compositions for inducing an immune response using conserved element constructs18 Aug 2026US 12,709,635 B2The United States of America, as represented by the Secretary, Department of Health and Human Services
- Compositions and methods for generating immunity to bacterial infection8 Oct 2026US 2026/0306601 A1Syntiron LLC
- Dengue virus serotype-specific modulation of t cell responses8 Oct 2026US 2026/0306621 A1The United States Government as represented by the Department of Veterans Affairs
- Treatment involving non-immunogenic rna for antigen vaccination8 Oct 2026US 2026/0306625 A1BioNTech SE
- Bacterial type iv secretion systems, methods of use for in vivo dna delivery, and method of engineering8 Oct 2026US 2026/0308604 A1University of Kentucky Research Foundation
- Compositions and methods for treatment or prventative treatment of cancer including triple negative breast cancer and/or lung cancer24 Sep 2026US 2026/0284165 A1The Medical College of Wisconsin, Inc.
Most cited
By later US patents
- Immunostimulatory nucleic acid molecules472US 6,207,646 B1Coley Pharmaceutical Group, Inc. · 2001
- Immunostimulatory nucleic acid molecules461US 6,239,116 B1Coley Pharmaceutical Group, Inc. · 2001
- Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant395US 6,406,705 B1Coley Pharmaceutical GmbH · 2002
- Immunomodulatory oligonucleotides335US 6,194,388 B1Coley Pharmaceutical Group, Inc. · 2001
- Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines290US 6,218,371 B1University of Iowa Research Foundation · 2001